Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Income from Continuing Operations (2016 - 2025)

Moleculin Biotech's Income from Continuing Operations history spans 10 years, with the latest figure at 7524000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 7524000.0 for Q4 2025, down 14.07% from a year ago — trailing twelve months through Dec 2025 was 24998000.0 (up 4.19% YoY), and the annual figure for FY2025 was 24998000.0, up 4.19%.
  • Income from Continuing Operations for Q4 2025 was 7524000.0 at Moleculin Biotech, down from 5867000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5517000.0 in Q2 2021 to a low of 40965000.0 in Q4 2023.
  • The 5-year median for Income from Continuing Operations is 6516000.0 (2024), against an average of 10477300.0.
  • The sharpest move saw Income from Continuing Operations plummeted 810.5% in 2021, then skyrocketed 83.9% in 2024.
  • Year by year, Income from Continuing Operations stood at 24028000.0 in 2021, then crashed by 35.75% to 32618000.0 in 2022, then decreased by 25.59% to 40965000.0 in 2023, then skyrocketed by 83.9% to 6596000.0 in 2024, then fell by 14.07% to 7524000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 7524000.0, 5867000.0, and 5694000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.